Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
Abstract Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples...
Main Authors: | Qi-Fan Yang, Di Wu, Jian Wang, Li Ba, Chen Tian, Yu-Ting Liu, Yue Hu, Li Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-92115-0 |
Similar Items
-
Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer
by: Yuan Zhuang, et al.
Published: (2021-03-01) -
Identification of a Prognostic Model Based on Immune-Related Genes of Lung Squamous Cell Carcinoma
by: Rui Li, et al.
Published: (2020-09-01) -
Prognostic Significance of the Lung Immune Prognostic Index in Patients with Resected Esophageal Squamous Cell Carcinoma
by: Feng JF, et al.
Published: (2021-03-01) -
A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis
by: Tao Fan, et al.
Published: (2021-06-01) -
Development and Validation of a Robust Immune Prognostic Signature for Head and Neck Squamous Cell Carcinoma
by: Yu Qiu, et al.
Published: (2020-11-01)